drugset / Trial / NCT03843528
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to evaluate the maximum tolerated (MTD) of vorinostat used in combination with low-dose azacitidine after allogeneic hematopoietic cell transplantation (alloHCT) for prevention of relapse of childhood myeloid malignancies.
Timeline
- Start
- 2019-05-01
- Primary completion
- 2027-07-30
- Completion
- 2027-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vorinostat | Small molecule | 100 mg/m2 | Oral |
| Background | Azacitidine | Other / unclassified | 32 mg/m2 | Intravenous |